Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies

Shigeki Kusamura, Dario Baratti, Marcello Deraco

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Objective: To evaluate the learning curve of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in treating peritoneal surface malignancies (PSM). Summary AND Background: CRS and HIPEC to treat PSM is a complex procedure with a significant morbidity. A long-lasting training program is required to acquire expertise in this type of operation. Methods: We performed CRS using peritonectomy procedures. HIPEC through the closed abdomen technique employed cisplatin and mitomycin-C or cisplatin and doxorubicin. Risk-adjusted sequential probability ratio test was used to assess the learning curve on a series of 420 cases of PSM on the basis of rates of incomplete cytoreduction and G3-5 morbidity (NCI-CTCAE v3). We determined control limits setting the type I/II error rates and unacceptable odds ratios (ORs) for the outcomes being studied. We performed the risk adjustment using logistic regression model. Results: Rates of incomplete cytoreduction, G3-5 morbidity, and postoperative mortality rates were 10.2%, 28.5%, and 2.1%, respectively. The risk-adjusted sequential probability ratio test curve crossed the lower control limit at the 137th and 149th case, respectively, for incomplete cytoreduction and G3-5 morbidity. At those points, the actual ORs are lower than the prespecified ORs for outcomes being studied. Therefore, we estimated that approximately 140 cases are necessary to ensure surgical proficiency in CRS and HIPEC. Conclusions: CRS and HIPEC to treat PSM has a steep learning curve requiring 140 procedures to acquire expertise.

Original languageEnglish
Pages (from-to)348-356
Number of pages9
JournalAnnals of Surgery
Volume255
Issue number2
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Learning Curve
Drug Therapy
Morbidity
Odds Ratio
Neoplasms
Cisplatin
Logistic Models
Risk Adjustment
Mitomycin
Abdomen
Doxorubicin
Education
Mortality

ASJC Scopus subject areas

  • Surgery

Cite this

@article{12c14b330d104a60aac725915df271b5,
title = "Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies",
abstract = "Objective: To evaluate the learning curve of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in treating peritoneal surface malignancies (PSM). Summary AND Background: CRS and HIPEC to treat PSM is a complex procedure with a significant morbidity. A long-lasting training program is required to acquire expertise in this type of operation. Methods: We performed CRS using peritonectomy procedures. HIPEC through the closed abdomen technique employed cisplatin and mitomycin-C or cisplatin and doxorubicin. Risk-adjusted sequential probability ratio test was used to assess the learning curve on a series of 420 cases of PSM on the basis of rates of incomplete cytoreduction and G3-5 morbidity (NCI-CTCAE v3). We determined control limits setting the type I/II error rates and unacceptable odds ratios (ORs) for the outcomes being studied. We performed the risk adjustment using logistic regression model. Results: Rates of incomplete cytoreduction, G3-5 morbidity, and postoperative mortality rates were 10.2{\%}, 28.5{\%}, and 2.1{\%}, respectively. The risk-adjusted sequential probability ratio test curve crossed the lower control limit at the 137th and 149th case, respectively, for incomplete cytoreduction and G3-5 morbidity. At those points, the actual ORs are lower than the prespecified ORs for outcomes being studied. Therefore, we estimated that approximately 140 cases are necessary to ensure surgical proficiency in CRS and HIPEC. Conclusions: CRS and HIPEC to treat PSM has a steep learning curve requiring 140 procedures to acquire expertise.",
author = "Shigeki Kusamura and Dario Baratti and Marcello Deraco",
year = "2012",
month = "2",
doi = "10.1097/SLA.0b013e3182436c28",
language = "English",
volume = "255",
pages = "348--356",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies

AU - Kusamura, Shigeki

AU - Baratti, Dario

AU - Deraco, Marcello

PY - 2012/2

Y1 - 2012/2

N2 - Objective: To evaluate the learning curve of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in treating peritoneal surface malignancies (PSM). Summary AND Background: CRS and HIPEC to treat PSM is a complex procedure with a significant morbidity. A long-lasting training program is required to acquire expertise in this type of operation. Methods: We performed CRS using peritonectomy procedures. HIPEC through the closed abdomen technique employed cisplatin and mitomycin-C or cisplatin and doxorubicin. Risk-adjusted sequential probability ratio test was used to assess the learning curve on a series of 420 cases of PSM on the basis of rates of incomplete cytoreduction and G3-5 morbidity (NCI-CTCAE v3). We determined control limits setting the type I/II error rates and unacceptable odds ratios (ORs) for the outcomes being studied. We performed the risk adjustment using logistic regression model. Results: Rates of incomplete cytoreduction, G3-5 morbidity, and postoperative mortality rates were 10.2%, 28.5%, and 2.1%, respectively. The risk-adjusted sequential probability ratio test curve crossed the lower control limit at the 137th and 149th case, respectively, for incomplete cytoreduction and G3-5 morbidity. At those points, the actual ORs are lower than the prespecified ORs for outcomes being studied. Therefore, we estimated that approximately 140 cases are necessary to ensure surgical proficiency in CRS and HIPEC. Conclusions: CRS and HIPEC to treat PSM has a steep learning curve requiring 140 procedures to acquire expertise.

AB - Objective: To evaluate the learning curve of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in treating peritoneal surface malignancies (PSM). Summary AND Background: CRS and HIPEC to treat PSM is a complex procedure with a significant morbidity. A long-lasting training program is required to acquire expertise in this type of operation. Methods: We performed CRS using peritonectomy procedures. HIPEC through the closed abdomen technique employed cisplatin and mitomycin-C or cisplatin and doxorubicin. Risk-adjusted sequential probability ratio test was used to assess the learning curve on a series of 420 cases of PSM on the basis of rates of incomplete cytoreduction and G3-5 morbidity (NCI-CTCAE v3). We determined control limits setting the type I/II error rates and unacceptable odds ratios (ORs) for the outcomes being studied. We performed the risk adjustment using logistic regression model. Results: Rates of incomplete cytoreduction, G3-5 morbidity, and postoperative mortality rates were 10.2%, 28.5%, and 2.1%, respectively. The risk-adjusted sequential probability ratio test curve crossed the lower control limit at the 137th and 149th case, respectively, for incomplete cytoreduction and G3-5 morbidity. At those points, the actual ORs are lower than the prespecified ORs for outcomes being studied. Therefore, we estimated that approximately 140 cases are necessary to ensure surgical proficiency in CRS and HIPEC. Conclusions: CRS and HIPEC to treat PSM has a steep learning curve requiring 140 procedures to acquire expertise.

UR - http://www.scopus.com/inward/record.url?scp=84855830266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855830266&partnerID=8YFLogxK

U2 - 10.1097/SLA.0b013e3182436c28

DO - 10.1097/SLA.0b013e3182436c28

M3 - Article

C2 - 22202584

AN - SCOPUS:84855830266

VL - 255

SP - 348

EP - 356

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 2

ER -